A 12 week randomized, double-blind, force-titration, parallel group, multi centre, phase IIIb study to compare the efficacy of rosuvastatin with atorvastatin and placebo in the treatment of non-diabetic, non-atheroscleric, metabolic syndrome subjects with raised LDL-C [low density lipoprotein cholesterol] and a 10 year risk of CHD [coronary heart disease] greater than 10 percent.

Trial Profile

A 12 week randomized, double-blind, force-titration, parallel group, multi centre, phase IIIb study to compare the efficacy of rosuvastatin with atorvastatin and placebo in the treatment of non-diabetic, non-atheroscleric, metabolic syndrome subjects with raised LDL-C [low density lipoprotein cholesterol] and a 10 year risk of CHD [coronary heart disease] greater than 10 percent.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2009

At a glance

  • Drugs Atorvastatin; Rosuvastatin
  • Indications Hypercholesterolaemia; Hyperlipidaemia; Lipid metabolism disorders; Metabolic syndrome
  • Focus Biomarker; Therapeutic Use
  • Acronyms COMETS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 Nov 2009 Actual end date (Feb 2005) added as reported by ClinicalTrials.gov.
    • 02 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top